Navigation Links
Arpida Reports Interim Results For Six Months to 30 June 2009
Date:8/19/2009

REINACH, Switzerland, August 19 /PRNewswire-FirstCall/ -- Arpida Ltd (SIX: ARPN) announced today its financial results for the six months ending 30 June 2009.

    Key events 2009 to date

    - Regulatory setback for intravenous iclaprim in cSSSI in U.S.A.
    - Strategic options under review
    - Company restructuring completed

Cash and financial investments of CHF 22.7 million at 30 June 2009

CFO Harry Welten, MBA, commented: "Our cost-saving measures have been implemented, resulting in a substantial reduction of the cash burn. We expect to have cash and financial investments of around CHF 14 million at the end of 2009."

Dr Jurgen Raths, President and CEO, commented: "Arpida is going through challenging times. We've completed a painful restructuring process in anticipation of a possible strategic deal. We remain fully committed to finding a strategic partner and securing the maximum value for our shareholders. Discussions are ongoing, as soon as these advance, we will provide an update."

The full 10 page text is available under: http://www.arpida.com

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Contacts:


'/>"/>
SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
2. Arpida to Discuss Strategy With Shareholders
3. Arpida Announces Full Year 2008 Financial Results
4. Arpida to Restructure and Focus on Key Projects
5. Arpidas iclaprim MAA Accepted for Review by EMEA
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
8. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
9. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
10. Arpida Announces Conference Call on 17 April
11. Arpida Announces Agenda Items for Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... for cells and tissues  ("BioLife" or the "Company"), today ... Stockholders on May 4, 2015 (the "Annual Meeting"). ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ...
(Date:12/24/2014)... The report expects global cell isolation and expansion ... a carefully analyzed data about the vital drivers, restraints, trends, ... of Report @ http://bit.ly/1yUxy0T , According to the ... growth at an impressive CAGR during near future. It expects ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... R&D Directions honors Dr. Sellers, pioneering work in human ... KNDL ), a leading, global full-service clinical research ... and General Manager of the company,s Early Stage Unit ... People in R&D" by leading industry publication R&D ...
... March 26 MacroGenics, Inc., a privately held biotechnology ... and infectious diseases, today announced the appointment of Eric ... very pleased that we have been able to attract ... MacroGenics," said Dr. Scott Koenig, President and CEO. ...
... Md., March 26 Novavax, Inc. (Nasdaq: NVAX ... quarter financial results in a press release to be issued ... Company will hold an investor conference call to discuss its ... 2009. The call will be hosted by Novavax President and ...
Cached Biology Technology:Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D' 2Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D' 3MacroGenics Appoints New Vice President of Business Development 2MacroGenics Appoints New Vice President of Business Development 3Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 2Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 3
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. One major ... multimodal biometric systems. Multimodal biometric systems utilize more than ...
(Date:12/10/2014)... a leader in performance biometric data sensor technology, today ... licensees for highly accurate, clinically validated biometric technology. This ... fitness and health sectors, but first responders/military and gaming ... as useful as the biometric data it delivers. As ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... lotion which glows under ultraviolet light have shown that ... properly cleaned. Their findings, published in BioMed Centrals journal, ... nasty bacteria Clostridium difficile (C. difficile) linger in the ... Michelle Alfa and a team of scientists from ...
... by ... providing volunteer coaching, SOUTHFIELD, Mich., May 9 The Center ... Moore, one of,its examiners, as a volunteer coach for trainees working ... been with the CCF for 3 years, will lend his 8 ...
... ... the platypus is one odd duck-billed, egg-laying, lactating ... aquatic lifestyle and the poison spurs that decorate males, ... development. But LSUs Mark Batzer, along with an international ... University in Saint Louis, Mo., has taken this theory ...
Cached Biology News:UV lotion lights the way to cleaner facilities 2Center for Computer Forensics Offers Expert to Volunteer as CFCE Certification Applicants Coach 2First analysis of platypus genome may impact disease prevention 2
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
ANTI 5-HYDROXYTRYPTOPHAN CONJ....
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: